Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders

SAN DIEGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$SAGE #ClassAction–Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE) breached their fiduciary duties to shareholders. Sage Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes medicines to treat central nervous system (CNS) disorders.

If you suffered a loss as a result of Sage Therapeutics’ misconduct, click here.

Sage Therapeutics, Inc. (SAGE) Shareholders Have Legal Options

Contact us to learn more:

Leonid Kandinov

(800) 350-6003

[email protected]
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leonid Kandinov

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

[email protected]
(619) 525-3990 or Toll Free (800) 350-6003

www.robbinsllp.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

For the last half century, thousands of communications professionals have turned to us to deliver their news to the audiences most important to their business through the sources they trust most. Over that time, we've gone from a single office with one full time employee to more than 500 employees in 32 bureaus.